세계의 당뇨병성 황반부종(DME) 시장 보고서(2025년)

Diabetic macular edema (DME) is a diabetes-related complication characterized by fluid accumulation in the macula, the central part of the retina responsible for sharp vision. This swelling occurs due to damaged blood vessels leaking fluid and proteins into the retinal tissue, leading to vision impairment or potential blindness if left untreated. DME is a leading cause of vision loss among diabetic patients and is closely linked to diabetic retinopathy.

The primary treatments for diabetic macular edema (DME) include anti-VEGF therapy, corticosteroids, laser therapy, and surgical intervention. Anti-VEGF therapy works by inhibiting vascular endothelial growth factor (VEGF), a protein that promotes abnormal blood vessel growth and retinal leakage, contributing to DME. The disease progresses through different stages, including early, moderate, and advanced stages. Patient demographics are categorized by age groups, including adults, the elderly, and children. Routes of administration include intravitreal injection, topical application, and systemic methods, with distribution channels such as hospital pharmacies, retail pharmacies, and online pharmacies.

The diabetic macular edema (DME) market research report is one of a series of new reports from The Business Research Company that provides diabetic macular edema (DME) market statistics, including the diabetic macular edema (DME) industry's global market size, regional shares, competitors with a diabetic macular edema (DME) market share, detailed diabetic macular edema (DME) market segments, market trends and opportunities, and any further data you may need to thrive in the diabetic macular edema (DME) industry. This diabetic macular edema (DME) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The diabetic macular edema (DME) market size has grown steadily in recent years. It will grow from $4.67 billion in 2024 to $4.89 billion in 2025 at a compound annual growth rate (CAGR) of 4.7%. The growth in the historic period can be attributed to the rise in the prevalence of diabetes, an increase in edema-related disorders, the growing prevalence of diabetic eye diseases, a surge in the geriatric population, and an increase in cases of blindness.

The diabetic macular edema (DME) market size is expected to see steady growth in the next few years. It will grow to $5.82 billion in 2029 at a compound annual growth rate (CAGR) of 4.4%. The anticipated growth during the forecast period is driven by improved healthcare access, increased government healthcare funding, greater awareness of diabetic complications, the growing adoption of telemedicine for eye care, and the expansion of specialized diabetic eye care centers. Key trends include the development of anti-VEGF therapies, the adoption of corticosteroid implants, advancements in drug delivery systems, innovations in retinal laser treatments, AI-powered diagnostic tools, and the increasing use of minimally invasive surgical techniques.

The rising prevalence of diabetes is anticipated to propel the growth of the diabetic macular edema (DME) market. Factors such as sedentary lifestyles, unhealthy dietary habits, increasing obesity rates, aging populations, and genetic predisposition contribute to the growing incidence of diabetes. This condition leads to diabetic macular edema by damaging retinal blood vessels, causing fluid leakage into the macula and resulting in swelling. For example, in June 2023, the Institute for Health Metrics and Evaluation, a US-based public health research institute, reported that over half a billion people worldwide were living with diabetes. This number is projected to more than double, reaching 1.3 billion by 2050. Consequently, the increasing prevalence of diabetes is driving the expansion of the diabetic macular edema (DME) market.

Leading companies in the diabetic macular edema (DME) treatment sector are emphasizing technological advancements, particularly in drug therapies, to enhance patient management and treatment outcomes. These advanced drug therapies incorporate innovative technologies and research to improve treatment efficacy, minimize side effects, and provide better results for patients. For instance, in March 2022, Novartis AG, a Switzerland-based pharmaceutical company, announced the European Commission's approval of Beovu for treating visual impairment caused by diabetic macular edema (DME). This approval was based on Phase III KESTREL and KITE study findings, which demonstrated Beovu's comparable effectiveness to aflibercept in improving vision over a one-year period. Additionally, more than half of the patients treated with Beovu maintained a 12-week treatment schedule, experiencing fewer instances of retinal fluid compared to those treated with aflibercept.

In July 2024, Merck & Co Inc, a US-based pharmaceutical company, acquired Eyebiotech Limited for $1.3 billion. This acquisition strengthens Merck & Co.'s portfolio, enhances research capabilities, and provides access to Restoret (EYE-103), a promising treatment for diabetic macular edema (DME) and treatment-naive neovascular age-related macular degeneration (AMD). Through this acquisition, the company aims to address significant unmet needs in ophthalmology. Eyebiotech Limited (EyeBio) is a UK-based biotechnology company specializing in ophthalmology.

Major players in the diabetic macular edema (dme) market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Novartis AG, Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals, Carl Zeiss Meditec AG, Bausch & Lomb, Santen Pharmaceutical Co. Ltd., Carl Zeiss AG, Topcon Corporation, Ypsomed AG, ARKRAY Inc, Hugel Inc., Optos plc, Noven Pharmaceuticals Inc., Alimera Sciences Inc., and Allergan plc.

North America was the largest region in the diabetic macular edema (DME) market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in diabetic macular edema (DME) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the diabetic macular edema (DME) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The diabetic macular edema (DME) market consists of revenues earned by entities by providing services such as retinal imaging, fluorescein angiography, visual acuity testing, and laser therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The diabetic macular edema market includes sales of ranibizumab, aflibercep, fluocinolone acetonide intravitreal implant, and dexamethasone intravitreal implant. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Diabetic Macular Edema (DME) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on diabetic macular edema (dme) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for diabetic macular edema (dme) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The diabetic macular edema (dme) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Anti-VEGF Therapy; Corticosteroids; Laser Therapy; Surgical Intervention
• 2) By Disease Stage: Early Stage; Moderate Stage; Advanced Stage
• 3) By Patient Demographics: Adults; Elderly; Children
• 4) By Route Of Administration: Intravitreal Injection; Topical; Systemic
• 5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Anti-VEGF Therapy: Monoclonal Antibodies; Recombinant Protein-Based Therapies
• 2) By Corticosteroids: Intravitreal Steroid Injections; Injectable Sustained-Release Corticosteroids
• 3) By Laser Therapy: Focal Laser Photocoagulation; Panretinal Photocoagulation
• 4) By Surgical Intervention: Vitrectomy; Membrane Peeling
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche AG; Merck & Co. Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Diabetic Macular Edema (DME) Market Characteristics

3. Diabetic Macular Edema (DME) Market Trends And Strategies

4. Diabetic Macular Edema (DME) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Diabetic Macular Edema (DME) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Diabetic Macular Edema (DME) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Diabetic Macular Edema (DME) Market Growth Rate Analysis
• 5.4. Global Diabetic Macular Edema (DME) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Diabetic Macular Edema (DME) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Diabetic Macular Edema (DME) Total Addressable Market (TAM)

6. Diabetic Macular Edema (DME) Market Segmentation

• 6.1. Global Diabetic Macular Edema (DME) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anti-VEGF Therapy
• Corticosteroids
• Laser Therapy
• Surgical Intervention
• 6.2. Global Diabetic Macular Edema (DME) Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Early Stage
• Moderate Stage
• Advanced Stage
• 6.3. Global Diabetic Macular Edema (DME) Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adults
• Elderly
• Children
• 6.4. Global Diabetic Macular Edema (DME) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravitreal Injection
• Topical
• Systemic
• 6.5. Global Diabetic Macular Edema (DME) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.6. Global Diabetic Macular Edema (DME) Market, Sub-Segmentation Of Anti-VEGF Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Recombinant Protein-Based Therapies
• 6.7. Global Diabetic Macular Edema (DME) Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravitreal Steroid Injections
• Injectable Sustained-Release Corticosteroids
• 6.8. Global Diabetic Macular Edema (DME) Market, Sub-Segmentation Of Laser Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Focal Laser Photocoagulation
• Panretinal Photocoagulation
• 6.9. Global Diabetic Macular Edema (DME) Market, Sub-Segmentation Of Surgical Intervention, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vitrectomy
• Membrane Peeling

7. Diabetic Macular Edema (DME) Market Regional And Country Analysis

• 7.1. Global Diabetic Macular Edema (DME) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Diabetic Macular Edema (DME) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Diabetic Macular Edema (DME) Market

• 8.1. Asia-Pacific Diabetic Macular Edema (DME) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Diabetic Macular Edema (DME) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Diabetic Macular Edema (DME) Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Diabetic Macular Edema (DME) Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Diabetic Macular Edema (DME) Market

• 9.1. China Diabetic Macular Edema (DME) Market Overview
• 9.2. China Diabetic Macular Edema (DME) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Diabetic Macular Edema (DME) Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Diabetic Macular Edema (DME) Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Diabetic Macular Edema (DME) Market

• 10.1. India Diabetic Macular Edema (DME) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Diabetic Macular Edema (DME) Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Diabetic Macular Edema (DME) Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Diabetic Macular Edema (DME) Market

• 11.1. Japan Diabetic Macular Edema (DME) Market Overview
• 11.2. Japan Diabetic Macular Edema (DME) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Diabetic Macular Edema (DME) Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Diabetic Macular Edema (DME) Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Diabetic Macular Edema (DME) Market

• 12.1. Australia Diabetic Macular Edema (DME) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Diabetic Macular Edema (DME) Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Diabetic Macular Edema (DME) Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Diabetic Macular Edema (DME) Market

• 13.1. Indonesia Diabetic Macular Edema (DME) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Diabetic Macular Edema (DME) Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Diabetic Macular Edema (DME) Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Diabetic Macular Edema (DME) Market

• 14.1. South Korea Diabetic Macular Edema (DME) Market Overview
• 14.2. South Korea Diabetic Macular Edema (DME) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Diabetic Macular Edema (DME) Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Diabetic Macular Edema (DME) Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Diabetic Macular Edema (DME) Market

• 15.1. Western Europe Diabetic Macular Edema (DME) Market Overview
• 15.2. Western Europe Diabetic Macular Edema (DME) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Diabetic Macular Edema (DME) Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Diabetic Macular Edema (DME) Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Diabetic Macular Edema (DME) Market

• 16.1. UK Diabetic Macular Edema (DME) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Diabetic Macular Edema (DME) Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Diabetic Macular Edema (DME) Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Diabetic Macular Edema (DME) Market

• 17.1. Germany Diabetic Macular Edema (DME) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Diabetic Macular Edema (DME) Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Diabetic Macular Edema (DME) Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Diabetic Macular Edema (DME) Market

• 18.1. France Diabetic Macular Edema (DME) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Diabetic Macular Edema (DME) Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Diabetic Macular Edema (DME) Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Diabetic Macular Edema (DME) Market

• 19.1. Italy Diabetic Macular Edema (DME) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Diabetic Macular Edema (DME) Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Diabetic Macular Edema (DME) Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Diabetic Macular Edema (DME) Market

• 20.1. Spain Diabetic Macular Edema (DME) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Diabetic Macular Edema (DME) Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Diabetic Macular Edema (DME) Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Diabetic Macular Edema (DME) Market

• 21.1. Eastern Europe Diabetic Macular Edema (DME) Market Overview
• 21.2. Eastern Europe Diabetic Macular Edema (DME) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Diabetic Macular Edema (DME) Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Diabetic Macular Edema (DME) Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Diabetic Macular Edema (DME) Market

• 22.1. Russia Diabetic Macular Edema (DME) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Diabetic Macular Edema (DME) Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Diabetic Macular Edema (DME) Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Diabetic Macular Edema (DME) Market

• 23.1. North America Diabetic Macular Edema (DME) Market Overview
• 23.2. North America Diabetic Macular Edema (DME) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Diabetic Macular Edema (DME) Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Diabetic Macular Edema (DME) Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Diabetic Macular Edema (DME) Market

• 24.1. USA Diabetic Macular Edema (DME) Market Overview
• 24.2. USA Diabetic Macular Edema (DME) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Diabetic Macular Edema (DME) Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Diabetic Macular Edema (DME) Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Diabetic Macular Edema (DME) Market

• 25.1. Canada Diabetic Macular Edema (DME) Market Overview
• 25.2. Canada Diabetic Macular Edema (DME) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Diabetic Macular Edema (DME) Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Diabetic Macular Edema (DME) Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Diabetic Macular Edema (DME) Market

• 26.1. South America Diabetic Macular Edema (DME) Market Overview
• 26.2. South America Diabetic Macular Edema (DME) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Diabetic Macular Edema (DME) Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Diabetic Macular Edema (DME) Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Diabetic Macular Edema (DME) Market

• 27.1. Brazil Diabetic Macular Edema (DME) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Diabetic Macular Edema (DME) Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Diabetic Macular Edema (DME) Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Diabetic Macular Edema (DME) Market

• 28.1. Middle East Diabetic Macular Edema (DME) Market Overview
• 28.2. Middle East Diabetic Macular Edema (DME) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Diabetic Macular Edema (DME) Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Diabetic Macular Edema (DME) Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Diabetic Macular Edema (DME) Market

• 29.1. Africa Diabetic Macular Edema (DME) Market Overview
• 29.2. Africa Diabetic Macular Edema (DME) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Diabetic Macular Edema (DME) Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Diabetic Macular Edema (DME) Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Diabetic Macular Edema (DME) Market Competitive Landscape And Company Profiles

• 30.1. Diabetic Macular Edema (DME) Market Competitive Landscape
• 30.2. Diabetic Macular Edema (DME) Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Diabetic Macular Edema (DME) Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Boehringer Ingelheim International GmbH
• 31.3. Regeneron Pharmaceuticals
• 31.4. Carl Zeiss Meditec AG
• 31.5. Bausch & Lomb
• 31.6. Santen Pharmaceutical Co. Ltd.
• 31.7. Carl Zeiss AG
• 31.8. Topcon Corporation
• 31.9. Ypsomed AG
• 31.10. ARKRAY Inc
• 31.11. Hugel Inc.
• 31.12. Optos plc
• 31.13. Noven Pharmaceuticals Inc.
• 31.14. Alimera Sciences Inc.
• 31.15. Allergan plc

32. Global Diabetic Macular Edema (DME) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Diabetic Macular Edema (DME) Market

34. Recent Developments In The Diabetic Macular Edema (DME) Market

35. Diabetic Macular Edema (DME) Market High Potential Countries, Segments and Strategies

• 35.1 Diabetic Macular Edema (DME) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Diabetic Macular Edema (DME) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Diabetic Macular Edema (DME) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer